Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.65 +0.37 (+0.77%)
Streaming Delayed Price Updated: 10:47 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 Next >
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Is DoubleVerify’s 39% Haircut a Buying Opportunity?
Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings 
Via MarketBeat
Topics Artificial Intelligence Fraud Malware
Exposures Artificial Intelligence Information Security Legal
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
From Pinnacle Group International
Via ACN Newswire
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Pfizer and Sanofi shares fall, which one to scoop up?
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows 
Via MarketBeat
Exposures COVID-19
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.